{"id":31668,"date":"2025-11-19T21:43:04","date_gmt":"2025-11-19T21:43:04","guid":{"rendered":"https:\/\/www.tun.com\/home\/?p=31668"},"modified":"2025-11-19T21:43:06","modified_gmt":"2025-11-19T21:43:06","slug":"researchers-develop-new-antibodies-that-inhibit-inflammation-in-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/www.tun.com\/home\/researchers-develop-new-antibodies-that-inhibit-inflammation-in-autoimmune-diseases\/","title":{"rendered":"Researchers Develop New Antibodies That Inhibit Inflammation in Autoimmune Diseases"},"content":{"rendered":"\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-uagb-blockquote uagb-block-e7eb3fc3 uagb-blockquote__skin-border uagb-blockquote__stack-img-none\"><blockquote class=\"uagb-blockquote\"><div class=\"uagb-blockquote__content\">Researchers led by UMC Utrecht have developed pioneering antibodies that inhibit inflammation in autoimmune diseases by targeting specific immune receptor sites. This breakthrough opens promising avenues for novel treatments.<\/div><footer><div class=\"uagb-blockquote__author-wrap uagb-blockquote__author-at-left\"><\/div><\/footer><\/blockquote><\/div>\n\n\n\n<div class=\"wp-block-group is-content-justification-space-between is-nowrap is-layout-flex wp-container-core-group-is-layout-b0ffac9c wp-block-group-is-layout-flex\"><div style=\"font-size:16px\" class=\"has-text-align-left wp-block-post-author\"><div class=\"wp-block-post-author__content\"><p class=\"wp-block-post-author__name\">The University Network<\/p><\/div><\/div>\n\n\n<div class=\"wp-block-uagb-social-share uagb-social-share__outer-wrap uagb-social-share__layout-horizontal uagb-block-ee584a31\">\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-ec619ce7\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/www.facebook.com\/sharer.php?u=\" tabindex=\"0\" role=\"button\" aria-label=\"facebook\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M504 256C504 119 393 8 256 8S8 119 8 256c0 123.8 90.69 226.4 209.3 245V327.7h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.28c-30.8 0-40.41 19.12-40.41 38.73V256h68.78l-11 71.69h-57.78V501C413.3 482.4 504 379.8 504 256z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n\n\n\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-32d99934\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/twitter.com\/share?url=\" tabindex=\"0\" role=\"button\" aria-label=\"twitter\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n\n\n\n<div class=\"wp-block-uagb-social-share-child uagb-ss-repeater uagb-ss__wrapper uagb-block-1d136f14\"><span class=\"uagb-ss__link\" data-href=\"https:\/\/www.linkedin.com\/shareArticle?url=\" tabindex=\"0\" role=\"button\" aria-label=\"linkedin\"><span class=\"uagb-ss__source-wrap\"><span class=\"uagb-ss__source-icon\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 448 512\"><path d=\"M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z\"><\/path><\/svg><\/span><\/span><\/span><\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">An international team of researchers led by UMC Utrecht has announced a breakthrough in the fight against autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and immune thrombocytopenia (ITP). The team has developed and characterized two first-in-class antibodies, C01 and C04, which specifically block the high-affinity IgG receptor Fc\u03b3RI, also known as CD64. This groundbreaking discovery could pave the way for new treatments aimed at reducing inflammation and tissue damage in various autoimmune conditions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The research, <a href=\"https:\/\/www.nature.com\/articles\/s41467-025-65133-z\" target=\"_blank\" rel=\"noopener\" title=\"\">published<\/a> today in Nature Communications, was spearheaded by Jeanette Leusen, a full professor in the Antibody Therapy research group at UMC Utrecht&#8217;s Center for Translational Immunology, and carried out by doctoral candidate Tosca Holtrop. The project was a collaborative effort involving experts from Kiel University in Germany, Leiden University Medical Center, Utrecht University and Friedrich-Alexander University Erlangen-N\u00fcrnberg in Germany.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In autoimmune diseases, the immune system mistakenly targets the body&#8217;s own tissues, leading to chronic inflammation. Fc\u03b3RI plays a significant role in this process by binding to immunoglobulin G (IgG) antibodies and triggering cellular functions like phagocytosis and cytokine production. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Normally, Fc\u03b3RI is activated by immune complexes \u2014 clusters of antibodies bound to pathogens. In autoimmune diseases, however, the production of autoantibodies leads to the formation of immune complexes that activate Fc\u03b3RI unnecessarily, resulting in persistent inflammation and tissue damage.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For over three decades, scientists have attempted to generate antibodies against the IgG-binding domain of CD64, but the receptor&#8217;s high affinity for IgG made this challenging. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The researchers overcame this hurdle by using the UMAB immunization method combined with novel phage display antibody libraries. This approach enabled them to discover the unique Fc-silent antibodies C01 and C04, which bind exclusively via their Fab domains to Fc\u03b3RI.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Quantitative binding studies revealed that both antibodies have a higher affinity for Fc\u03b3RI than human IgG, allowing them to displace IgG or pathogenic immune complexes efficiently. Critically, neither antibody triggered Fc\u03b3RI activation, which distinguishes them from earlier attempts that inadvertently caused further inflammation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In laboratory models, C01 and C04 effectively inhibited the binding of opsonized platelets to immune cells in ITP patients, and significantly reduced IgG-dependent platelet depletion in preclinical models. Additionally, in models for rheumatoid arthritis, the antibodies inhibited the binding of patient-derived autoantibody-immune complexes to monocytes, macrophages and neutrophils.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cI think we found the needle in the haystack, after searching over a decade and thanks to a true team effort,\u201d Leusen added. \u201cEach research partner contributed a critical piece, from antibody discovery and structure determination to patient sample testing and preclinical models. Only together could we bring this to fruition. These antibodies not only provide a unique tool for studying Fc\u03b3RI biology, but also hold promise as therapeutic candidates in autoimmune and infectious diseases.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The next steps for the research team include enhancing the antibodies&#8217; affinity, humanizing the initially mouse-derived antibodies to reduce immunogenicity, and seeking partners for clinical development.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The antibodies have already been patented by the Utrecht Holdings, highlighting the significant potential of this discovery. <\/p>\n\n\n\n<div style=\"height:14px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Source: <\/strong><a href=\"https:\/\/research.umcutrecht.nl\/news\/new-antibodies-developed-that-can-inhibit-inflammation-in-autoimmune-diseases\/\" target=\"_blank\" rel=\"noopener\" title=\"\">University Medical Center Utrecht<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>An international team of researchers led by UMC Utrecht has announced a breakthrough in the fight against autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and immune thrombocytopenia (ITP). The team has developed and characterized two first-in-class antibodies, C01 and C04, which specifically block the high-affinity IgG receptor Fc\u03b3RI, also known as [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"single-no-separators","format":"standard","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[25],"tags":[515,513,514,344],"class_list":["post-31668","post","type-post","status-publish","format-standard","hentry","category-science","tag-friedrich-alexander-university-erlangen-nurnberg","tag-kiel-university","tag-leiden-university-medical-center","tag-utrecht-university"],"acf":[],"aioseo_notices":[],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false},"uagb_author_info":{"display_name":"The University Network","author_link":"https:\/\/www.tun.com\/home\/author\/funky_junkie\/"},"uagb_comment_info":0,"uagb_excerpt":"An international team of researchers led by UMC Utrecht has announced a breakthrough in the fight against autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and immune thrombocytopenia (ITP). The team has developed and characterized two first-in-class antibodies, C01 and C04, which specifically block the high-affinity IgG receptor Fc\u03b3RI, also known as&hellip;","_links":{"self":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/31668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/comments?post=31668"}],"version-history":[{"count":9,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/31668\/revisions"}],"predecessor-version":[{"id":31763,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/posts\/31668\/revisions\/31763"}],"wp:attachment":[{"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/media?parent=31668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/categories?post=31668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tun.com\/home\/wp-json\/wp\/v2\/tags?post=31668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}